Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children

The antiretroviral drug nevirapine and the antimalarial artemisinin-based combination therapy artemether-lumefantrine are commonly co-administered to treat malaria in the context of HIV. Nevirapine is a known inhibitor of cytochrome P450 3A4, which metabolizes artemether and lumefantrine. To address...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2017-10, Vol.12 (10), p.e0186589
Hauptverfasser:	Huang, Liusheng, Carey, Vincent, Lindsey, Jane C, Marzan, Florence, Gingrich, David, Graham, Bobbie, Barlow-Mosha, Linda, Ssemambo, Phionah K, Kamthunzi, Portia, Nachman, Sharon, Parikh, Sunil, Aweeka, Francesca T
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired immune deficiency syndrome Africa South of the Sahara AIDS Antimalarials - pharmacokinetics Antiretroviral agents Antiretroviral drugs Antiretroviral therapy Artemether Artemisinin Artemisinins - administration & dosage Artemisinins - pharmacokinetics Biology and Life Sciences Child Child, Preschool Children Clinical outcomes Collaboration Complications and side effects Control methods Cytochrome Cytochrome P450 Dihydroartemisinin Dosage and administration Drug dosages Drug therapy Drugs Enrollments Ethanolamines - administration & dosage Ethanolamines - pharmacokinetics Exposure Female Fluorenes - administration & dosage Fluorenes - pharmacokinetics HIV Human immunodeficiency virus Humans Lumefantrine Malaria Male Medicine Medicine and Health Sciences Nevirapine Nevirapine - therapeutic use Parasites People and Places Pharmacokinetics Pharmacology Pharmacy Plasmodium falciparum Public health Therapy Vector-borne diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!